Kathleen M. Murphy
Research Subjects
Kathleen M. Murphy has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Karin D. Berg
Laboratory Corporation of America, Research Triangle Park, North Carolina
6 shared publicationsMichael J. Hafez
Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland
5 shared publicationsConstance A. Griffin
‡Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland
3 shared publicationsAlexis Norris-Kirby
Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
2 shared publicationsBrigitte M. Ronnett
Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland
2 shared publicationsJames R. Eshleman
Departments of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, MD
2 shared publications
Latest Publications
- 1 March 2016
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 35 (2) , 134-141
Invasive Complete Hydatidiform Moles
Complete hydatidiform moles (CHM) are purely androgenetic conceptions, with most (∼85%) arising from fertilization of an egg lacking maternal DNA by a single sperm that duplicates (homozygous/monospermic 46,XX) and a small subset arising via fertilization by 2 sperms (heterozygous/dispermic 46,XY or 46,XX). It remains controversial if heterozygous/dispermic CHMs have a significantly greater risk of persistent gestational trophoblastic disease. Analysis of zygosity of CHMs with and without invasion at presentation, including invasive CHMs with concurrent atypical trophoblastic proliferations concerning for or consistent with choriocarcinoma, has not been specifically addressed. In a prospective series of 1024 products of conception specimens subjected to immunohistochemical analysis of p57 expression and molecular genotyping with short tandem-repeat markers, 288 CHMs were diagnosed, of which 126 were genotyped, including 16 invasive CHMs. Zygosity was compared between those with and without invasion. Of the 16 study cases, 12 (75%) were homozygous/monospermic XX and 4 (25%) were heterozygous/dispermic (3 XY and 1 XX). Of the 110 genotyped noninvasive CHMs, 96 (87%) were homozygous/monospermic XX and 14 (13%) were heterozygous/dispermic (12 XY, 2 XX). Comparison of the zygosity results for the invasive CHMs (study group) with the noninvasive CHMs in the database did not demonstrate a statistically significant difference (P=0.24, Fisher exact test). In addition, of the 3 cases associated with metastatic gestational trophoblastic disease (pulmonary nodules) at presentation, 2 were homozygous/monospermic XX, indicating that this form is not without risk of significant gestational trophoblastic disease. Thus, the current study has demonstrated a higher frequency of heterozygous/dispermic CHMs among invasive cases compared with those lacking invasion, but does not support the use of zygosity data for risk assessment of CHMs. A persistent, unresolved diagnostic challenge identified in some invasive CHMs is interpretation of accompanying florid atypical trophoblastic proliferations which raise concern for choriocarcinoma. Future studies should address the need for reproducible diagnostic criteria and molecular biomarkers for distinguishing florid hyperplastic from malignant neoplastic trophoblastic proliferations.
- 1 March 2016
- Published by Wolters Kluwer Health in International Journal of Gynecological Pathology
- Vol. 35 (2) , 134-141
Invasive Complete Hydatidiform Moles
Complete hydatidiform moles (CHM) are purely androgenetic conceptions, with most (∼85%) arising from fertilization of an egg lacking maternal DNA by a single sperm that duplicates (homozygous/monospermic 46,XX) and a small subset arising via fertilization by 2 sperms (heterozygous/dispermic 46,XY or 46,XX). It remains controversial if heterozygous/dispermic CHMs have a significantly greater risk of persistent gestational trophoblastic disease. Analysis of zygosity of CHMs with and without invasion at presentation, including invasive CHMs with concurrent atypical trophoblastic proliferations concerning for or consistent with choriocarcinoma, has not been specifically addressed. In a prospective series of 1024 products of conception specimens subjected to immunohistochemical analysis of p57 expression and molecular genotyping with short tandem-repeat markers, 288 CHMs were diagnosed, of which 126 were genotyped, including 16 invasive CHMs. Zygosity was compared between those with and without invasion. Of the 16 study cases, 12 (75%) were homozygous/monospermic XX and 4 (25%) were heterozygous/dispermic (3 XY and 1 XX). Of the 110 genotyped noninvasive CHMs, 96 (87%) were homozygous/monospermic XX and 14 (13%) were heterozygous/dispermic (12 XY, 2 XX). Comparison of the zygosity results for the invasive CHMs (study group) with the noninvasive CHMs in the database did not demonstrate a statistically significant difference (P=0.24, Fisher exact test). In addition, of the 3 cases associated with metastatic gestational trophoblastic disease (pulmonary nodules) at presentation, 2 were homozygous/monospermic XX, indicating that this form is not without risk of significant gestational trophoblastic disease. Thus, the current study has demonstrated a higher frequency of heterozygous/dispermic CHMs among invasive cases compared with those lacking invasion, but does not support the use of zygosity data for risk assessment of CHMs. A persistent, unresolved diagnostic challenge identified in some invasive CHMs is interpretation of accompanying florid atypical trophoblastic proliferations which raise concern for choriocarcinoma. Future studies should address the need for reproducible diagnostic criteria and molecular biomarkers for distinguishing florid hyperplastic from malignant neoplastic trophoblastic proliferations.
- 1 July 2010
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 12 (4) , 525-529
Abnormal Villous Morphology Associated with Triple Trisomy of Paternal Origin
- 1 July 2010
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 12 (4) , 525-529
Abnormal Villous Morphology Associated with Triple Trisomy of Paternal Origin
- 1 November 2009
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 11 (6) , 598-605
Molecular Genotyping of Hydatidiform Moles
- 1 November 2009
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 11 (6) , 598-605
Molecular Genotyping of Hydatidiform Moles
- 1 July 2009
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 11 (4) , 359-363
A Rare e14a3 (b3a3) BCR-ABL Fusion Transcript in Chronic Myeloid Leukemia
- 1 July 2009
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 11 (4) , 359-363
A Rare e14a3 (b3a3) BCR-ABL Fusion Transcript in Chronic Myeloid Leukemia
- 1 July 2007
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 9 (3) , 408-413
Constitutional Duplication of a Region of Chromosome Yp Encoding AMELY, PRKY, and TBL1Y
- 1 July 2007
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 9 (3) , 408-413
Constitutional Duplication of a Region of Chromosome Yp Encoding AMELY, PRKY, and TBL1Y
- 31 August 2005
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 7 (3) , 422-426
Bone Marrow Engraftment Analysis after Granulocyte Transfusion
- 31 August 2005
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 7 (3) , 422-426
Bone Marrow Engraftment Analysis after Granulocyte Transfusion
- Open Access
- 1 January 2005
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 51 (1) , 35-39
Sequencing of Genomic DNA by Combined Amplification and Cycle Sequencing Reaction
Background: Despite considerable advances, DNA sequencing has remained somewhat time-consuming and expensive, requiring three separate steps to generate sequencing products from a template: amplification of the target sequence; purification of the amplified product; and a sequencing reaction. Our aim was to develop a method to routinely combine PCR amplification and cycle sequencing into one single reaction, enabling direct sequencing of genomic DNA.
- 1 January 2005
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 51 (1) , 35-39
Open AccessSequencing of Genomic DNA by Combined Amplification and Cycle Sequencing Reaction
Background: Despite considerable advances, DNA sequencing has remained somewhat time-consuming and expensive, requiring three separate steps to generate sequencing products from a template: amplification of the target sequence; purification of the amplified product; and a sequencing reaction. Our aim was to develop a method to routinely combine PCR amplification and cycle sequencing into one single reaction, enabling direct sequencing of genomic DNA.
- Open Access
- 30 July 2004
- Published by Wiley in British Journal of Haematology
- Vol. 126 (6) , 785-791
FLT3 mutations in myeloid sarcoma
Summary: Myeloid sarcoma is an extramedullary tumour that typically occurs in the setting of acute myeloid leukaemia (AML), or myeloproliferative disorders. In AML, two types of mutations in Fms‐like tyrosine kinase 3 (FLT3) have been described; internal tandem duplications (ITD) and point mutations at aspartic acid residue 835 (D835). We analysed 24 myeloid sarcoma specimens from 20 patients for FLT3 ITD and D835 mutations. FLT3 ITD mutations were identified in three of 20 cases (15%); no D835 mutations were identified. The ITD inserts ranged in size from 33 to 198 base pairs (bp) and represented approximately 20–40% of the FLT3 alleles. Two cases showed discordance in FLT3 ITD mutational status. In one case, the leukaemia specimen was positive for a FLT3 ITD mutation and the myeloid sarcoma specimen was negative. In the second case, the myeloid sarcoma was positive for a FLT3 ITD mutation at diagnosis, but negative in subsequent relapse samples. Our findings suggest that small molecule inhibitors of FLT3 may be useful therapeutic agents for treatment of myeloid sarcomas‐containing FLT3 mutations, however, the potential for discordance between the leukaemia and myeloid sarcoma, necessitates that the myeloid sarcoma tumour itself be analysed for FLT3 mutations.
- 30 July 2004
- Published by Wiley in British Journal of Haematology
- Vol. 126 (6) , 785-791
Open AccessFLT3 mutations in myeloid sarcoma
Summary: Myeloid sarcoma is an extramedullary tumour that typically occurs in the setting of acute myeloid leukaemia (AML), or myeloproliferative disorders. In AML, two types of mutations in Fms‐like tyrosine kinase 3 (FLT3) have been described; internal tandem duplications (ITD) and point mutations at aspartic acid residue 835 (D835). We analysed 24 myeloid sarcoma specimens from 20 patients for FLT3 ITD and D835 mutations. FLT3 ITD mutations were identified in three of 20 cases (15%); no D835 mutations were identified. The ITD inserts ranged in size from 33 to 198 base pairs (bp) and represented approximately 20–40% of the FLT3 alleles. Two cases showed discordance in FLT3 ITD mutational status. In one case, the leukaemia specimen was positive for a FLT3 ITD mutation and the myeloid sarcoma specimen was negative. In the second case, the myeloid sarcoma was positive for a FLT3 ITD mutation at diagnosis, but negative in subsequent relapse samples. Our findings suggest that small molecule inhibitors of FLT3 may be useful therapeutic agents for treatment of myeloid sarcomas‐containing FLT3 mutations, however, the potential for discordance between the leukaemia and myeloid sarcoma, necessitates that the myeloid sarcoma tumour itself be analysed for FLT3 mutations.
- 1 November 2003
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 3 (6) , 811-818
Mutation and single nucleotide polymorphism detection using temperature gradient capillary electrophoresis
Rapid, high-throughput mutation and single nucleotide polymorphism detection technologies are necessary to identify sequence alterations responsible for human disease. Several screening techniques have been developed as alternatives to the costly and time-consuming task of direct gene sequencing. Unfortunately, many of these techniques have relatively low mutation detection sensitivities and/or require significant up-front assay optimization. Temperature gradient capillary electrophoresis is a relatively new mutation screening technology that capitalizes on the denaturing effects of temperature and the high resolution capacity of capillary electrophoresis to detect heteroduplexes formed between mutant and wild type gene sequences. The utility of temperature gradient capillary electrophoresis for the detection of known sequence alterations and as a tool for mutation discovery is reviewed.
- 1 November 2003
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 3 (6) , 811-818
Mutation and single nucleotide polymorphism detection using temperature gradient capillary electrophoresis
Rapid, high-throughput mutation and single nucleotide polymorphism detection technologies are necessary to identify sequence alterations responsible for human disease. Several screening techniques have been developed as alternatives to the costly and time-consuming task of direct gene sequencing. Unfortunately, many of these techniques have relatively low mutation detection sensitivities and/or require significant up-front assay optimization. Temperature gradient capillary electrophoresis is a relatively new mutation screening technology that capitalizes on the denaturing effects of temperature and the high resolution capacity of capillary electrophoresis to detect heteroduplexes formed between mutant and wild type gene sequences. The utility of temperature gradient capillary electrophoresis for the detection of known sequence alterations and as a tool for mutation discovery is reviewed.
- 1 November 2003
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 5 (4) , 222-226
A Single Nucleotide Primer Extension Assay to Detect the APC I1307K Gene Variant
- 1 November 2003
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 5 (4) , 222-226
A Single Nucleotide Primer Extension Assay to Detect the APC I1307K Gene Variant